TITLE 77: PUBLIC HEALTH
CHAPTER I: DEPARTMENT OF PUBLIC HEALTH
SUBCHAPTER k: COMMUNICABLE DISEASE CONTROL AND IMMUNIZATIONS
PART 690 CONTROL OF COMMUNICABLE DISEASES CODE
SECTION 690.469 INFLUENZA A, VARIANT VIRUS (REPORTABLE BY TELEPHONE IMMEDIATELY, WITHIN THREE HOURS UPON INITIAL CLINICAL SUSPICION OR LABORATORY TEST ORDER)
Section 690.469 Influenza A, Variant Virus (Reportable by telephone immediately, within three hours upon initial clinical suspicion or laboratory test order)
a) Control of Case
1) Standard precautions, including routine use of eye protection, and droplet precautions shall be followed for patients in health care settings (e.g., hospitals, long-term care facilities, outpatient offices, emergency transport vehicles), use of a respirator at least as protective as an N-95 is recommended during aerosol-generating procedures. When feasible, aerosol-generating procedures should be conducted in an airborne infection isolation room. The Department will make further recommendations as more information becomes known about the transmissibility of the variant influenza virus.
2) If present rules are not adequate, alternative requirements may be issued. See Section 690.100(d).
b) Control of Contracts
1) The Department will make recommendations for control of contracts based on transmissibility and severity of the illness that caused the variant influenza strain.
2) Health care workers caring for patients with variant influenza shall be monitored for illness by the health care facility, in collaboration with the local health department.
c) Laboratory Testing and Reporting
1) Virus isolation studies on respiratory specimens from individuals with suspect variant influenza infection should not be performed by clinical laboratories unless approved by the Department.
2) Laboratories shall immediately report to the local health authority any request for laboratory testing for a variant subtype, or laboratory identification of a suspect variant subtype, in a human specimen. Variant influenza includes that which is different from currently circulating human influenza H1 and H3 viruses. Variant subtypes include, but are not limited to, H2, H5, H7 and H9 subtypes. Influenza H1 and H3 subtypes originating from a non-human species or from genetic reassortment between animal and human viruses are also variant subtypes. Laboratory evidence of a suspect variant subtype includes any specimen from a human that is polymerase chain reaction or culture positive for influenza A and tests negative for currently circulating H1 and H3 subtypes.
3) Upon request, laboratories shall forward clinical materials to the Department's laboratory.
(Source: Amended at 38 Ill. Reg. 5533, effective February 11, 2014)